Does the media refer more to MNOV or FHTX?

In the previous week, MediciNova and MediciNova both had 2 articles in the media. MediciNova's average media sentiment score of 0.59 beat Foghorn Therapeutics' score of -0.31 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ACIU or MNOV more profitable?

AC Immune has a net margin of -1,788.02% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% MediciNova -1,962.98% -27.28% -25.24%

Is HUMA or MNOV more profitable?

MediciNova has a net margin of -1,962.98% compared to Humacyte's net margin of -4,836.06%. MediciNova's return on equity of -27.28% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% MediciNova -1,962.98% -27.28% -25.24%

Does the media prefer FATE or MNOV?

In the previous week, MediciNova had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for Fate Therapeutics. MediciNova's average media sentiment score of 0.59 beat Fate Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

MediciNova (MNOV) Competitors

$1.33 -0.03 (-2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$1.33 0.00 (0.00%)

As of 07:51 PM Eastern

Compare

MNOV vs. FHTX, EDIT, ACIU, HUMA, and FATE

Should you buy MediciNova stock or one of its competitors? MarketBeat compares MediciNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediciNova include Foghorn Therapeutics (FHTX), Editas Medicine (EDIT), AC Immune (ACIU), Humacyte (HUMA), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.

How does MediciNova compare to Foghorn Therapeutics?

MediciNova (NASDAQ:MNOV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, MediciNova and MediciNova both had 2 articles in the media. MediciNova's average media sentiment score of 0.59 beat Foghorn Therapeutics' score of -0.31 indicating that MediciNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Foghorn Therapeutics has a net margin of -266.88% compared to MediciNova's net margin of -1,962.98%. Foghorn Therapeutics' return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

MediciNova has higher earnings, but lower revenue than Foghorn Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	159.66	-$12M	-$0.23	N/A
Foghorn Therapeutics	$30.91M	7.75	-$74.28M	-$1.16	N/A

MediciNova currently has a consensus price target of $8.33, indicating a potential upside of 526.57%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 180.11%. Given MediciNova's higher possible upside, equities analysts clearly believe MediciNova is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market.

Summary

MediciNova and Foghorn Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does MediciNova compare to Editas Medicine?

MediciNova (NASDAQ:MNOV) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MediciNova currently has a consensus target price of $8.33, indicating a potential upside of 526.57%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 92.86%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

MediciNova has higher earnings, but lower revenue than Editas Medicine. MediciNova is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	159.66	-$12M	-$0.23	N/A
Editas Medicine	$40.52M	6.77	-$160.06M	-$1.23	N/A

In the previous week, MediciNova had 2 more articles in the media than Editas Medicine. MarketBeat recorded 2 mentions for MediciNova and 0 mentions for Editas Medicine. MediciNova's average media sentiment score of 0.59 beat Editas Medicine's score of 0.00 indicating that MediciNova is being referred to more favorably in the media.

Company	Overall Sentiment
MediciNova	Positive
Editas Medicine	Neutral

Editas Medicine has a net margin of -281.59% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

MediciNova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Summary

MediciNova beats Editas Medicine on 11 of the 17 factors compared between the two stocks.

How does MediciNova compare to AC Immune?

AC Immune (NASDAQ:ACIU) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

MediciNova has lower revenue, but higher earnings than AC Immune. MediciNova is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	59.98	-$85.03M	-$0.82	N/A
MediciNova	$410K	159.66	-$12M	-$0.23	N/A

51.4% of AC Immune shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MediciNova had 2 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for MediciNova and 0 mentions for AC Immune. AC Immune's average media sentiment score of 1.16 beat MediciNova's score of 0.59 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Positive
MediciNova	Positive

AC Immune has a net margin of -1,788.02% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
MediciNova	-1,962.98%	-27.28%	-25.24%

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 195.28%. MediciNova has a consensus target price of $8.33, indicating a potential upside of 526.57%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

MediciNova beats AC Immune on 11 of the 17 factors compared between the two stocks.

How does MediciNova compare to Humacyte?

Humacyte (NASDAQ:HUMA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Humacyte presently has a consensus price target of $6.25, indicating a potential upside of 795.80%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 526.57%. Given Humacyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Humacyte is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

In the previous week, MediciNova had 2 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for MediciNova and 0 mentions for Humacyte. MediciNova's average media sentiment score of 0.59 beat Humacyte's score of -0.50 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Negative
MediciNova	Positive

MediciNova has lower revenue, but higher earnings than Humacyte. MediciNova is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	75.93	-$40.83M	-$0.57	N/A
MediciNova	$410K	159.66	-$12M	-$0.23	N/A

MediciNova has a net margin of -1,962.98% compared to Humacyte's net margin of -4,836.06%. MediciNova's return on equity of -27.28% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
MediciNova	-1,962.98%	-27.28%	-25.24%

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MediciNova beats Humacyte on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, MediciNova had 1 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for Fate Therapeutics. MediciNova's average media sentiment score of 0.59 beat Fate Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova has lower revenue, but higher earnings than Fate Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	36.11	-$136.32M	-$1.09	N/A
MediciNova	$410K	159.66	-$12M	-$0.23	N/A

MediciNova has a net margin of -1,962.98% compared to Fate Therapeutics' net margin of -2,056.79%. MediciNova's return on equity of -27.28% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
MediciNova	-1,962.98%	-27.28%	-25.24%

Fate Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 148.79%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 526.57%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

MediciNova beats Fate Therapeutics on 12 of the 16 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.94M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-5.78	20.68	25.17	23.98
Price / Sales	159.66	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.56	8.26	10.76	6.41
Net Income	-$12M	$23.91M	$3.56B	$337.14M
7 Day Performance	-0.75%	3.05%	1.37%	-0.48%
1 Month Performance	-5.00%	2.40%	0.81%	0.49%
1 Year Performance	-2.21%	56.35%	30.53%	28.16%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	2.1637 of 5 stars	$1.33 -2.2%	$8.33 +526.6%	+3.8%	$66.94M	$410K	N/A	10
FHTX Foghorn Therapeutics	2.4059 of 5 stars	$4.01 -2.4%	$11.43 +185.0%	-15.3%	$241.31M	$30.91M	N/A	120	Analyst Downgrade Gap Up
EDIT Editas Medicine	2.658 of 5 stars	$2.36 -4.1%	$5.40 +128.8%	+31.4%	$240.85M	$40.52M	N/A	230
ACIU AC Immune	2.4043 of 5 stars	$2.37 +1.3%	$7.50 +216.5%	+33.9%	$238.15M	$4.31M	N/A	140	Positive News
HUMA Humacyte	3.408 of 5 stars	$1.03 -3.7%	$6.57 +538.0%	-68.3%	$237.56M	$2.04M	N/A	150	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. FHTX, EDIT, ACIU, HUMA, and FATE

How does MediciNova compare to Foghorn Therapeutics?

Summary

How does MediciNova compare to Editas Medicine?

Summary

How does MediciNova compare to AC Immune?

Summary

How does MediciNova compare to Humacyte?

Summary

How does MediciNova compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. FHTX, EDIT, ACIU, HUMA, and FATE

How does MediciNova compare to Foghorn Therapeutics?

Does the media refer more to MNOV or FHTX?

Do insiders and institutionals have more ownership in MNOV or FHTX?

Is MNOV or FHTX more profitable?

Which has preferable valuation & earnings, MNOV or FHTX?

Do analysts rate MNOV or FHTX?

Which has more volatility & risk, MNOV or FHTX?

Summary

How does MediciNova compare to Editas Medicine?

Do insiders and institutionals believe in MNOV or EDIT?

Do analysts recommend MNOV or EDIT?

Which has stronger earnings and valuation, MNOV or EDIT?

Does the media refer more to MNOV or EDIT?

Is MNOV or EDIT more profitable?

Which has more risk & volatility, MNOV or EDIT?

Summary

How does MediciNova compare to AC Immune?

Which has more volatility and risk, ACIU or MNOV?

Which has higher valuation & earnings, ACIU or MNOV?

Do insiders & institutionals have more ownership in ACIU or MNOV?

Does the media prefer ACIU or MNOV?

Is ACIU or MNOV more profitable?

Do analysts rate ACIU or MNOV?

Summary

How does MediciNova compare to Humacyte?

Do analysts prefer HUMA or MNOV?

Which has more risk and volatility, HUMA or MNOV?

Does the media favor HUMA or MNOV?

Which has stronger valuation & earnings, HUMA or MNOV?

Is HUMA or MNOV more profitable?

Do institutionals and insiders have more ownership in HUMA or MNOV?

Summary

How does MediciNova compare to Fate Therapeutics?

Does the media prefer FATE or MNOV?

Which has stronger valuation & earnings, FATE or MNOV?

Is FATE or MNOV more profitable?

Which has more risk & volatility, FATE or MNOV?

Do analysts prefer FATE or MNOV?

Do institutionals & insiders believe in FATE or MNOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools